复星医药最新公告：控股子公司获药品补充申请批准

证券之星04-09

复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2626518842?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-09 17:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626518842","market":"sh","top_or_hot":-1,"title":"复星医药最新公告：控股子公司获药品补充申请批准","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600196\">复星医药</a>(600196.SH)公告称，公司控股子公司<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/51201020260409.png\"/><img src=\"https://static.stockstar.com/etf/51608020260409.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药最新公告：控股子公司获药品补充申请批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药最新公告：控股子公司获药品补充申请批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 17:29 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026040900027730.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026040900027730.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://stock.stockstar.com/RB2026040900027730.shtml","article_id":"2626518842","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626518842","pubTimestamp":1775726995,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1191":"制药","BK0188":"融资融券","BK0175":"白马股","BK0012":"证金概念","BK1593":"医美概念股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0096":"民营医院","BK0183":"MSCI概念","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK1515":"抗疫概念"},"translate_title":"Fosun Pharma's latest announcement: its holding subsidiary was approved for supplementary drug application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的汉利康(利妥昔单抗注射液)新增适应症的补充申请获国家药监局批准。本次新增适应症包括：联合维泊妥珠单抗等药物治疗既往未经治疗的弥漫大B细胞淋巴瘤(DLBCL)成人患者；联合苯达莫司汀和维泊妥珠单抗治疗不适合接受造血干细胞移植的复发或难治性DLBCL成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626518842","isCrawlerRequest":true}